RU2645261C2 - НОВЫЕ СВЯЗЫВАЮЩИЕ C5a НУКЛЕИНОВЫЕ КИСЛОТЫ - Google Patents

НОВЫЕ СВЯЗЫВАЮЩИЕ C5a НУКЛЕИНОВЫЕ КИСЛОТЫ Download PDF

Info

Publication number
RU2645261C2
RU2645261C2 RU2014132708A RU2014132708A RU2645261C2 RU 2645261 C2 RU2645261 C2 RU 2645261C2 RU 2014132708 A RU2014132708 A RU 2014132708A RU 2014132708 A RU2014132708 A RU 2014132708A RU 2645261 C2 RU2645261 C2 RU 2645261C2
Authority
RU
Russia
Prior art keywords
nucleic acid
absent
seq
acid molecule
disease
Prior art date
Application number
RU2014132708A
Other languages
English (en)
Russian (ru)
Other versions
RU2014132708A (ru
Inventor
Кай ХЕЛИГ
Аксель ФАТЕР
Клаус Бухнер
Кристиан Мааш
Свен Клуссманн
Original Assignee
Ноксон Фарма Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2012/000089 external-priority patent/WO2012095303A1/en
Application filed by Ноксон Фарма Аг filed Critical Ноксон Фарма Аг
Publication of RU2014132708A publication Critical patent/RU2014132708A/ru
Application granted granted Critical
Publication of RU2645261C2 publication Critical patent/RU2645261C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
RU2014132708A 2012-01-10 2013-01-10 НОВЫЕ СВЯЗЫВАЮЩИЕ C5a НУКЛЕИНОВЫЕ КИСЛОТЫ RU2645261C2 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
PCT/EP2012/000089 WO2012095303A1 (en) 2011-01-10 2012-01-10 Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same
EP12000106 2012-01-10
EPPCT/EP2012/000089 2012-01-10
EP12000106.0 2012-01-10
EP12006960 2012-10-08
EP12006960.4 2012-10-08
PCT/EP2013/000056 WO2013104540A1 (en) 2012-01-10 2013-01-10 New c5a binding nucleic acids

Publications (2)

Publication Number Publication Date
RU2014132708A RU2014132708A (ru) 2016-02-27
RU2645261C2 true RU2645261C2 (ru) 2018-02-19

Family

ID=48781063

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014132708A RU2645261C2 (ru) 2012-01-10 2013-01-10 НОВЫЕ СВЯЗЫВАЮЩИЕ C5a НУКЛЕИНОВЫЕ КИСЛОТЫ

Country Status (18)

Country Link
US (5) US9518265B2 (enExample)
EP (1) EP2802660B1 (enExample)
JP (1) JP6415327B2 (enExample)
KR (1) KR102034203B1 (enExample)
CN (1) CN104145018B (enExample)
AU (2) AU2013209131A1 (enExample)
BR (1) BR112014016877B1 (enExample)
CA (1) CA2860806C (enExample)
DK (1) DK2802660T3 (enExample)
ES (1) ES2786007T3 (enExample)
IL (1) IL233516B (enExample)
IN (1) IN2014DN05665A (enExample)
MX (1) MX362061B (enExample)
PL (1) PL2802660T3 (enExample)
PT (1) PT2802660T (enExample)
RU (1) RU2645261C2 (enExample)
SG (2) SG10201605594UA (enExample)
WO (1) WO2013104540A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2823245C2 (ru) * 2019-03-14 2024-07-23 МорфоСис АГ Антитела, нацеливающиеся на C5aR

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111443069A (zh) 2013-10-28 2020-07-24 多茨技术公司 过敏原检测
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
EP3793427B1 (en) 2018-05-17 2026-04-01 The Procter & Gamble Company Systems and methods for hair coverage analysis
US11172873B2 (en) 2018-05-17 2021-11-16 The Procter & Gamble Company Systems and methods for hair analysis
EP3586865A1 (en) * 2018-06-21 2020-01-01 Charité - Universitätsmedizin Berlin Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis
US11384357B2 (en) 2018-06-29 2022-07-12 The Procter And Gamble Company Aptamers for personal care applications
CN113383079B (zh) * 2018-11-12 2024-11-19 阿普塔里恩生物技术股份公司 Cxcl8结合性核酸
WO2020214784A1 (en) 2019-04-16 2020-10-22 The Procter & Gamble Company Aptamers for odor control applications
US12039732B2 (en) 2021-04-14 2024-07-16 The Procter & Gamble Company Digital imaging and learning systems and methods for analyzing pixel data of a scalp region of a users scalp to generate one or more user-specific scalp classifications
CN113150106B (zh) * 2021-04-26 2022-08-16 华中农业大学 来源于补体成分C5a的抗菌肽及其应用
TW202602466A (zh) 2024-03-20 2026-01-16 德商艾普塔里昂生技公司 以Ｃ５ａ抑制劑治療疾病之方法
EP4620474A1 (en) 2024-03-20 2025-09-24 APTARION biotech AG Method of treating a disorder with a c5a inhibitor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999041271A1 (en) * 1998-02-12 1999-08-19 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of complement system proteins
RU2007131267A (ru) * 2005-01-17 2009-02-27 Йерини Аг (De) АНТАГОНИСТЫ РЕЦЕПТОРА С5a

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US6140490A (en) 1996-02-01 2000-10-31 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of complement system proteins
US6395029B1 (en) 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
DK2431377T3 (en) 2001-10-26 2017-08-14 Noxxon Pharma Ag Modified L-nucleic acids
EP1306382A1 (de) 2001-10-26 2003-05-02 Noxxon Pharma AG Modifizierte L-Nukleinsäure
ATE441706T1 (de) 2002-02-20 2009-09-15 Gen Hospital Corp Konjugate mit biologisch abbaubarem polymer und verwendung dafür
MXPA05011022A (es) 2003-04-13 2006-04-27 Enzon Pharmaceuticals Inc Profarmacos oligonucleotidos polimericos.
GB0314472D0 (en) 2003-06-20 2003-07-23 Warwick Effect Polymers Ltd Polymer
US20070116710A1 (en) 2004-02-03 2007-05-24 Leonard Bell Methods of treating hemolytic anemia
US20090281296A1 (en) 2004-02-09 2009-11-12 Supramol Parenteral Colloid Gmbh Process for the production of conjugates from polysaccharides and polynucelotides
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
DK1727567T3 (da) * 2004-02-12 2013-10-14 Archemix Llc Aptamer-terapeutiske midler nyttige i behandling af komplementrelaterede forstyrrelser
WO2005099768A2 (en) 2004-03-23 2005-10-27 Complex Biosystems Gmbh Polymeric prodrug with a self-immolative linker
CA2585664C (en) 2004-11-05 2014-05-20 The Children's Hospital Of Philadelphia Biodegradable linkers for molecular therapies
EP2596807B1 (en) 2006-03-08 2015-12-16 Archemix LLC Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders
MX2009002859A (es) 2006-09-15 2009-03-30 Enzon Pharmaceuticals Inc Enlazadores biodegradables a base de ester impedido para suministro de oligonucleotidos.
EP2061901A2 (en) 2006-10-31 2009-05-27 Noxxon Pharma AG Methods for detection of a single- or double-stranded nucleic acid molecule
CA2700441A1 (en) * 2007-09-24 2009-04-02 Noxxon Pharma Ag C5a binding nucleic acids
WO2010103868A1 (ja) 2009-03-11 2010-09-16 オリンパスメディカルシステムズ株式会社 画像処理システム、その外部装置およびその画像処理方法
WO2010108657A2 (en) 2009-03-23 2010-09-30 Noxxon Pharma Ag C5a binding nucleic acids and the use thereof
EP2561079A1 (en) 2010-04-21 2013-02-27 Noxxon Pharma AG Lipid binding nucleic acids
EP2663640B1 (en) * 2011-01-10 2020-11-04 APTARION biotech AG Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same
KR20140083039A (ko) 2011-10-21 2014-07-03 녹손 파르마 아게 글루카곤 결합형 핵산
BR112014016939A2 (pt) 2012-01-10 2019-09-24 Noxxon Pharma Ag ácidos nucleicos que se ligam especificamente a cgrp

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999041271A1 (en) * 1998-02-12 1999-08-19 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of complement system proteins
RU2007131267A (ru) * 2005-01-17 2009-02-27 Йерини Аг (De) АНТАГОНИСТЫ РЕЦЕПТОРА С5a

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2823245C2 (ru) * 2019-03-14 2024-07-23 МорфоСис АГ Антитела, нацеливающиеся на C5aR

Also Published As

Publication number Publication date
US20140364487A1 (en) 2014-12-11
JP2015509705A (ja) 2015-04-02
PL2802660T3 (pl) 2020-07-27
CA2860806A1 (en) 2013-07-18
PT2802660T (pt) 2020-04-21
SG11201403771SA (en) 2014-07-30
US12188021B2 (en) 2025-01-07
EP2802660B1 (en) 2020-02-19
DK2802660T3 (da) 2020-05-18
JP6415327B2 (ja) 2018-10-31
MX2014008454A (es) 2015-02-05
AU2013209131A1 (en) 2014-07-10
US20180223285A1 (en) 2018-08-09
KR20140111703A (ko) 2014-09-19
IL233516A0 (en) 2014-08-31
KR102034203B1 (ko) 2019-10-18
CN104145018A (zh) 2014-11-12
MX362061B (es) 2019-01-07
RU2014132708A (ru) 2016-02-27
IL233516B (en) 2018-07-31
IN2014DN05665A (enExample) 2015-05-15
HK1198371A1 (en) 2015-04-10
US9518265B2 (en) 2016-12-13
SG10201605594UA (en) 2016-09-29
CN104145018B (zh) 2019-05-10
ES2786007T3 (es) 2020-10-08
US11492625B2 (en) 2022-11-08
US20240384275A1 (en) 2024-11-21
EP2802660A1 (en) 2014-11-19
US10590424B2 (en) 2020-03-17
CA2860806C (en) 2020-10-20
US20210163946A1 (en) 2021-06-03
WO2013104540A1 (en) 2013-07-18
BR112014016877B1 (pt) 2022-03-15
US20250327082A1 (en) 2025-10-23
AU2018271388B2 (en) 2021-03-11
BR112014016877A2 (pt) 2019-10-29
AU2018271388A1 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
US12188021B2 (en) C5a binding nucleic acids
JP5798320B2 (ja) Ｃ５ａに結合する核酸
JP2020500157A (ja) Ｃ３阻害のための組み合わせ治療
JP2012525124A (ja) ヘプシジン結合核酸
CA3009854A1 (en) Complement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders
US20240052006A1 (en) Anti-inflammatory cytokines and methods of use
US20120065254A1 (en) C5A binding nucleic acids and the use thereof
US11466276B2 (en) Stem-loop compositions and methods for inhibiting factor D
US12534734B2 (en) Stem-loop compositions and methods for inhibiting interleukin-8
EP4620474A1 (en) Method of treating a disorder with a c5a inhibitor
TW202602466A (zh) 以Ｃ５ａ抑制劑治療疾病之方法
HK1198371B (en) New c5a binding nucleic acids
AU2013204622B2 (en) Complement Binding Aptamers and Anti-C5 Agents Useful in the Treatment of Ocular Disorders
AU2016204713B2 (en) Complement Binding Aptamers and Anti-C5 Agents Useful in the Treatment of Ocular Disorders
HK1146296A (en) C5a binding nucleic acids

Legal Events

Date Code Title Description
PC41 Official registration of the transfer of exclusive right

Effective date: 20191126